Oral News and Research

RSS

First Edition: October 15, 2010

Today's top stories from major news organizations report on the effort by 20 states to challenge the federal health law, a new federal panel to inform consumers about health care options and the struggle to pay for cancer care.

15 Oct 2010

GfK HealthCare: RRMS patients anticipate availability of new oral therapies

Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.

15 Oct 2010

Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis

Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).

15 Oct 2010

Administering ondansetron drug to children is economically advantageous

Two years ago, a study by University of North Carolina at Chapel Hill researchers found that an anti-vomiting drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.Now a new economic analysis led by Canadian researchers, in collaboration with Michael J. Steiner, MD, assistant professor of pediatrics at UNC, concludes that routinely giving ondansetron to children with gastroenteritis-induced vomiting would prevent thousands of hospitalizations and save millions of dollars each year.

15 Oct 2010

Cubist third quarter total net revenues increase 13% to $162.1M

Cubist Pharmaceuticals, Inc. today announced results for the third quarter ended September 30, 2010.

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

$FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates$

FDA warns of risk of atypical thigh bone fracture in patients taking bisphosphonates

The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk. Bisphosphonates inhibit the loss of bone mass in people with osteoporosis.

14 Oct 2010

Watermelon effective against prehypertension

No matter how you slice it, watermelon has a lot going for it -- sweet, low calorie, high fiber, nutrient rich -- and now, there's more. Evidence from a pilot study led by food scientists at The Florida State University suggests that watermelon can be an effective natural weapon against prehypertension, a precursor to cardiovascular disease.

14 Oct 2010

World's third rectal microbicide trial launched in Pittsburgh

The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.

14 Oct 2010

Scientists suggest lemon-lime soft drink can improve effectiveness of oral anticancer drug

Experiments with an artificial stomach suggest that a popular lemon-lime soft drink could play an unexpected role in improving the effectiveness of an oral anticancer drug. The experiments produced evidence that patients will absorb more of the unnamed drug, tested in Phase I in clinical trials, when taken with "flat" or degassed Sprite. The study appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

14 Oct 2010

XenoPort to present XP23829 preclinical data at ECTRIMS meeting

XenoPort, Inc. announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Gothenburg, Sweden, October 13 - 16, 2010.

14 Oct 2010

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians are anticipating the arrival of new oral therapies for multiple sclerosis patients, with initial research showing very high awareness of oral candidates, particularly Novartis' Gilenya, which received FDA approval for relapsing forms of the disease in late September. The majority of neurologists expect Gilenya to be very useful as a therapy and trial of the drug is predicted to be strong, according to new research by GfK HealthCare.

13 Oct 2010

Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation

Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease. This program is presently in clinical development phase II.

13 Oct 2010

Kuwait Healthy Life Study to examine metabolic health in children

In the face of a dramatic worldwide increase in adolescent obesity and Type 2 diabetes, The Forsyth Institute today announced a research alliance with the Dasman Diabetes Institute of Kuwait to initiate studies that could lay a scientific basis for prevention. This collaboration, called The Kuwait Healthy Life Study, will examine conditions in children that predispose them to obesity and Type 2 diabetes.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

Tenofovir gel, a vaginal microbicide that has shown promise for preventing HIV through vaginal sex, is being tested in a new trial looking at its safety and acceptability when used rectally. The results of the study, being led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), will help determine if the gel should be evaluated further for its potential to prevent HIV among both men and women who engage in receptive anal intercourse.

13 Oct 2010

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Adeona Pharmaceuticals, Inc., announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline.

12 Oct 2010

Study finds link between malnutrition and prolonged hospital stay

Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.

12 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Generex to acquire majority interest in Global Medical Direct

Generex Biotechnology Corporation today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications.

11 Oct 2010